Helus Pharma to Present at Jefferies Global Healthcare Conference, Highlighting Progress in Novel Serotonergic Agonists

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. This announcement matters as it provides a platform for Helus Pharma to update the investment community on its lead programs, which target major depressive disorder (MDD) and generalized anxiety disorder (GAD)—conditions affecting millions worldwide.

Helus Pharma is developing HLP003, a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of MDD. Notably, HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which could accelerate its development and review. The company is also advancing HLP004, another proprietary NSA in Phase 2 for GAD. These programs address large unmet needs, as current treatments for depression and anxiety often have limited efficacy or significant side effects. The company’s NSAs are designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health.

The Jefferies conference participation is a key opportunity for Helus Pharma to highlight its clinical data and regulatory milestones. The company’s focus on proprietary NSAs positions it within a competitive landscape of psychedelic-inspired therapeutics, but its Breakthrough Therapy designation sets it apart. The fireside chat will likely cover the company’s Phase 3 trial design, upcoming data readouts, and the regulatory pathway for HLP003. Investors and analysts will be keen to hear about enrollment progress and any safety or efficacy signals from ongoing studies.

Helus Pharma, operating under the commercial name of Cybin Inc., was founded in 2019 and has since built a portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more details on the conference and company updates, visit the company’s newsroom at https://ibn.fm/HELP. The full press release is available at https://ibn.fm/1QdP7.

The implications of this announcement extend beyond the conference itself. It signals that Helus Pharma is actively engaging with the financial community as it approaches critical milestones. With mental health disorders on the rise globally, successful development of HLP003 and HLP004 could offer new options for patients who do not respond to existing therapies. The company’s participation in a prestigious healthcare conference like Jefferies Global Healthcare Conference also enhances its visibility among institutional investors, which could be crucial for future financing and partnership opportunities.

In summary, Helus Pharma’s upcoming presentation at the Jefferies conference underscores the importance of its clinical-stage pipeline and the potential impact of its novel approach to treating depression and anxiety. Stakeholders should monitor the webcast for insights into the company’s progress and strategic direction.